MicroRNA Mimics Based on the miR-15/107 Consensus Sequence Sensitise NSCLC Cells to Targeted Therapy.

Carien Carpenter, Nina Simmons, William J H Davis, Madeleine Thompson, Nico van Zandwijk, Catherine J Drummond, Glen Reid

Abstract read

PubMed Full text at PMC Publisher

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carien CarpenterDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand.

Nina SimmonsDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand.

William J H DavisDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand.

Madeleine ThompsonDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand.

Nico van ZandwijkSydney Local Health District, Sydney, NSW 2065, Australia.ORCID 0000-0002-8405-9688

Catherine J DrummondDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand.

Glen ReidDepartment of Pathology and Molecular Medicine, University of Otago, Dunedin 9054, New Zealand.ORCID 0000-0001-6465-5223

Funding

Otago Innovation Limited OIL2505

6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) is the leading cause of lung cancer deaths, with resistance to targeted therapies posing a major clinical challenge. Drug-tolerant persister (DTP) cells are key contributors to resistance, and targeting them offers new strategies to enhance existing treatments. MicroRNAs (miRNAs), particularly the tumour-suppressive miR-15/107 family, offer promise due to their ability to target multiple oncogenic pathways. This study evaluated a synthetic consensus miRNA mimic, conmiR-15/107, in NSCLC cell line models. Dose-response assays showed robust, dose-dependent growth inhibition in both EGFR-mutant (PC9) and KRAS-mutant (H358 and A549) lung adenocarcinoma cells, but not in the human bronchial epithelial cell line BEAS-2B. When combined with EGFR inhibitors (osimertinib and gefitinib) in PC9 cells, the mimics showed a higher rate of growth inhibition compared with the controls and reduced IC

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungErbB ReceptorsLung NeoplasmsMicroRNAsMolecular Targeted TherapyTyrosine Kinase InhibitorsAcetonitrilesAcrylamidesAniline CompoundsCell Line, TumorConsensus SequenceDrug Resistance, NeoplasmGefitinibHumansIndolesAcetonitrilesAcrylamidesadagrasibAniline CompoundsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsGefitinibIndolesKRAS protein, humanMicroRNAsMIRN107 microRNA, humanMIRN15 microRNA, humanosimertinibPiperazinesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasibTyrosine Kinase Inhibitorsdrug toleranceEGFRKRASlung adenocarcinomamicroRNAtargeted therapy

Identifiers

PMID41898563

DOI10.3390/ijms27062701

PMCPMC13026349

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.